RE: Exciting pipeline ahead13 Apr 2026 13:22
Wyn it’s important to remember that SGC is considered chemo-refractory with no existing standard of care. This is what Chris said in the December presentation:
“It is important to reiterate: although we are not seeing that high response rate, it’s primarily because this disease setting is notorious for lack of responses. It’s known to be chemo-refractory. On the flip side, PFS as an endpoint is well accepted. I mean, it’s one of the gold standard endpoints in oncology. It’s the question that patients ask: how long do I have? In general, the survival endpoints in metastatic disease are considered to be the standards, and objective response rate is used as a surrogate endpoint, as a surrogate for the survival endpoints that we see. I would say, having been a practising oncologist, that while large decreases in tumour size are nice to have, they’re really only meaningful when they’re accompanied by an extension in survival. Many oncology drugs are approved based on PFS, and one can look no further than one of the more recent approvals in breast cancer. This is an ADC known as Trodelvy, which, you know, the primary endpoints were both survival endpoints. It was overall survival and it was progression-free survival – and so I think that disease stabilisation and for prolonged periods of time, progression-free survival is almost more important than seeing responses. We are seeing tumour shrinkage, and in general it is accompanied, as Ruairidh mentioned in a few settings, it is accompanied by that prolonged disease stabilisation, or PFS. So we’re excited about the data. We’re highly encouraged that the Phase 1b looks to be right in line with the exciting data that we showed in the Phase 1a.”
Sign In
Follow the stocks
